5 recruiting, 4 not yet recruiting, 4 terminated, 3 active not recruiting. 17 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Recruiting 5, Not yet recruiting 4, Terminated 4, Active not recruiting 3, Completed 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow PSMA PET: new trials by email Literature Review of PSMA PET trials Research Report on PSMA PET
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Anti-cancer Drug DSP-5336 (Enzomenib) in Prostate Cancer Antiandrogen Therapy, Biopsy Procedure, Biospecimen Collection - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 24 | 2027-02-26 | 2026-11-12 |
| PSMA PET/MRI for Predicting and Detecting Prostate Cancer PSMA PET, MRI, 18F-DCFPyL - Prostate Cancer, High-Risk Localized Prostate Cancer | Phase 2 | Not yet recruiting | University of Wisconsin, Madison | 120 | 2026-12-01 | 2026-11-09 |
| Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial Lutetium Lu 177 Vipivotide Tetraxetan, Cell-free Circulating Tumor DNA Assay, Computed Tomography - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Recruiting | University of Washington | 64 | 2026-11-15 | 2026-10-19 |
| Pluvicto for the Treatment of African American Men With Metastatic Castration-Resistant Prostate Cancer Biopsy Procedure, Biospecimen Collection, Bone Scan - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Not yet recruiting | Emory University | 88 | 2026-11-02 | 2026-10-06 |
| Efficacy of Ra-223 in PSMA PET Optimally Selected Patients Radium-223, PSMA Positron Emission Tomography (PET) Scan, Technetium Tc 99M Medronate - Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone | Phase 2 | Active not recruiting | University of California, San Francisco | 2 | 2024-08-30 | 2026-01-14 |
| Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT) Computed Tomography, Gallium Ga 68 Gozetotide, Lutetium Lu 177 Vipivotide Tetraxetan - Prostate Carcinoma, Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8 | Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | 90 | 2024-08-01 | 2026-03-10 |
| Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study Apalutamide, Biopsy, Biospecimen Collection - Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma | Phase 2 | Terminated | University of Washington | 8 | 2024-05-23 | 2026-10-19 |
| Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation Biospecimen Collection, Carboplatin, Chest Radiography - Prostate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8 | Phase 2 | Recruiting | SWOG Cancer Research Network | 44 | 2024-03-01 | 2026-01-29 |
| Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer Biospecimen Collection, Bone Scan, Brachytherapy - Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8 | Phase 2 | Not yet recruiting | University of Kansas Medical Center | 90 | 2023-11-20 | 2023-11-13 |
| MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer MRI-guided Intensity-Modulated Radiation Therapy, Antiandrogen Therapy, PSMA PET Scan - Prostate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8 | Phase 2 | Terminated | Thomas Jefferson University | 6 | 2022-11-16 | 2026-03-03 |
| Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study Biospecimen Collection, Bone Scan, Computed Tomography - Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma | Phase 2 | Active not recruiting | NRG Oncology | 194 | 2022-04-20 | 2026-08-17 |
| MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer Pembrolizumab, Pemetrexed Disodium, Biospecimen Collection - Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma | Phase 2 | Active not recruiting | Mayo Clinic | 45 | 2021-07-23 | 2026-06-04 |
| Multi-modality Imaging (PCa) Using Sodium MRI and PSMA PET in Men Pre-prostatectomy PET Scan, [18F]PSMA-1007 Injection, Sodium MRI - Prostate Cancer, Prostate Adenocarcinoma | Phase 2 | Completed | Glenn Bauman | 16 | 2021-02-04 | 2026-09-18 |
| Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study Positron Emission Tomography, Lymphadenectomy, Radiation Therapy - Prostate Adenocarcinoma | Phase 2 | Recruiting | University of Washington | 100 | 2020-09-30 | 2026-07-07 |
| PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores F-DCFPyL Injection, PSMA PET - Prostate Cancer, Recurrent Prostate Cancer | Phase 2 / Phase 3 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 60 | 2019-12-18 | 2026-03-02 |
| SUV on PSMA PET/CT in Non-Prostate Tumors PSMA PET/CT - Cancer | Phase 2 | Terminated | Sir Mortimer B. Davis - Jewish General Hospital | 3 | 2019-07-25 | 2023-04-12 |
| Functional Microscale Organotypic Assays to Predict Patient Response to Anti-Angiogenesis Therapies PSMA-based 18F-DCFPyL PET tracer for PET/CT exams - Renal Cell Carcinoma | Phase 2 | Terminated | University of Wisconsin, Madison | 5 | 2018-12-08 | 2022-12-21 |
Prostatic Neoplasms (13) · Carcinoma, Adenoid Cystic (1) · Carcinoma, Renal Cell (1) · Kidney Neoplasms (1) · Neoplasms (1) · Salivary Gland Neoplasms (1)
University of Washington (3) · University of Wisconsin, Madison (2) · Emory University (1) · Glenn Bauman (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Jonsson Comprehensive Cancer Center (1) · Mayo Clinic (1) · NRG Oncology (1) · National Cancer Institute (NCI) (1) · SWOG Cancer Research Network (1) · Sir Mortimer B. Davis - Jewish General Hospital (1) · Thomas Jefferson University (1) · University of California, San Francisco (1) · University of Kansas Medical Center (1)
United States (14) · Canada (3)
Adel Mandl (1) · Ashish Chintakuntlawar, MBBS, PhD (1) · Bridget F Koontz (1) · Changhee Lee, MD (1) · Evan Yu (1) · Heather H Cheng (1) · Jacob E Berchuck, MD (1) · Jeremie Calais (1) · Jessie DiNome, MD (1) · Katherine A. Price, MD (1) · Kosj Yamoah, M.D., Ph.D. (1) · Michael Schweizer, MD (1) · Ruben Raychaudhuri, MD (1) · Stephen Pautler, MD, FRCSC (1) · Steve Cho, MD (1)
P30CA014520 (1), P30CA138292 (1), P30CA168524 (1), U10CA180868 (1), U10CA180888 (1), UM1CA186691 (1)